SCHEMBL19687731

SCHEMBL19687731

C=CC(O)N(Cc1cccnc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H3 Q13133 2/20 0.41
NR1H2 P55055 1/20 0.41
VNN1 O95497 3/20 0.39
UBE2M P61081 2/20 0.39
DCUN1D1 Q96GG9 2/20 0.39
HIF1A Q16665 1/20 0.38
EPAS1 Q99814 1/20 0.38
CHRNB2 P17787 2/20 0.38
CHRNA4 P43681 2/20 0.38
CACNA1H O95180 1/20 0.37
NR1D1 P20393 1/20 0.37
SORT1 Q99523 1/20 0.36
CETP P11597 1/20 0.36
GRM2 Q14416 2/20 0.36
KDM4E B2RXH2 1/20 0.35
POLB P06746 1/20 0.35
NAMPT P43490 1/20 0.35
FDPS P14324 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18763043 0.77 GSTO1 (0.50) NR1H3NR1H2VNN1UBE2MDCUN1D1
SCHEMBL25797239 0.72 CYP3A4 (0.53) NR1H3NR1H2HIF1AEPAS1CHRNB2
SCHEMBL28034152 0.68 CHRNB2 (0.43) NR1H3NR1H2HIF1AEPAS1CHRNB2
SCHEMBL7382021 0.67 CACNA1H (0.45) VNN1HIF1ACACNA1HSORT1KDM4E
SCHEMBL7381239 0.67 CACNA1H (0.45) VNN1HIF1ACACNA1HSORT1KDM4E
SCHEMBL6742580 0.66 KDM4E (0.43) VNN1CACNA1HSORT1KDM4EPOLB
SCHEMBL23059908 0.65 KIF11 (0.44)
SCHEMBL30062626 0.64 CACNA1H (0.53) NR1H3VNN1CACNA1HNR1D1SORT1
SCHEMBL27602785 0.64 HIF1A (0.65) NR1H3NR1H2VNN1HIF1AEPAS1
SCHEMBL10560010 0.64 GRM2 (0.57) GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200216507-A1 IN VIVO ENGINEERED CEREBLON PROTEIN VIVIDION THERAPEUTICS, INC. 2020-07-09 US disclosed
WO-2017205972-A1 SYSTEMS METHODS AND COMPOSITIONS FOR PREDICTING METASTASIS IN BLADDER CANCER GENOMEDX BIOSCIENCES, INC. (CA) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200216507-A1 IN VIVO ENGINEERED CEREBLON PROTEIN CRBN, CDR2, DCUN1D4 NR1H3 4049/4885NR1H2 4246/4885VNN1 933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.